Korean J Urol Oncol.
2022 Feb;20(1):1-11. 10.22465/kjuo.2022.20.1.1.
The Important Role of Poly ADP-Ribose Polymerase Inhibitor in Prostate Cancer
- Affiliations
-
- 1Department of Urology, Center for Urologic Cancer, Research Institute and Hospital of National Cancer Center, Goyang, Korea
- KMID: 2527246
- DOI: http://doi.org/10.22465/kjuo.2022.20.1.1
Abstract
- Poly (ADP-ribose) polymerase inhibitors (PARP inhibitor) is a new targeted drug for metastatic prostate cancer in which the patient has a mutation on homologous repair gene including BRCA1/2 gene. This drug was the first gene-based targeted agent in prostate cancer and there were more than 5 available drugs for PARP inhibitors. Only 4 were approved for clinical use for patients with cancer from the U.S. Food and Drug Administration. This review article deals with the overview of the PARP inhibitors and their use in future research and clinical fields.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Cisplatin induces primary necrosis through poly(ADP-ribose) polymerase 1 activation in kidney proximal tubular cells
- Melatonin Induces Apoptotic Cell Death via p53 in LNCaP Cells
- Poly (ADP-ribose) polymerase inhibitor: A new horizon in advanced prostate cancer treatment
- BRCA1/BRCA2 Pathogenic Variant Breast Cancer: Treatment and Prevention Strategies
- BRCA1 Reversion Mutation Confers Resistance to Olaparib and Camrelizumab in a Patient with Breast Cancer Liver Metastasis
